CatalYm GmbH
🇩🇪Germany
- Country
- 🇩🇪Germany
- Ownership
- Holding
- Established
- 2016-01-01
- Employees
- 11
- Market Cap
- -
- Website
- http://www.catalym.com
CatalYm's Visugromab Shows Promise in Enhancing Antibody-Drug Conjugate Efficacy by Blocking GDF-15
New preclinical data reveals that visugromab, CatalYm's GDF-15-neutralizing antibody, significantly enhances the anti-tumor activity of antibody-drug conjugates (ADCs) in multiple solid tumor models.
© Copyright 2025. All Rights Reserved by MedPath